James Basta Intellia Therapeutics, Inc. (NTLA) insider trading activity

James Basta is EVP, General Counsel of Intellia Therapeutics, Inc.. Currently has a direct ownership of 74,497 shares of NTLA, which is worth approximately $707,721. The most recent transaction as insider was on Jan 03, 2025, when has been sold 7,074 shares (Common Stock) at a price of $12.18 per share, resulting in proceeds of $86,161. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 74.5K

8.67% 3M change

44.73% 12M change

Total Value Held $707,721

JAMES BASTA Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 03 2025	SELL Open market or private sale	$86,161 $12.18 p/Share	7,074 Reduced 8.67%	74,497 Common Stock
Mar 04 2024	SELL Open market or private sale	$75,778 $32.99 p/Share	2,297 Reduced 2.74%	81,571 Common Stock
Mar 01 2024	BUY Grant, award, or other acquisition	-	32,394 Added 27.86%	83,868 Common Stock
Jan 03 2024	SELL Open market or private sale	$112,095 $29.46 p/Share	3,805 Reduced 6.88%	51,474 Common Stock
Mar 02 2023	SELL Open market or private sale	$47,741 $43.88 p/Share	1,088 Reduced 1.93%	55,279 Common Stock
Mar 01 2023	BUY Grant, award, or other acquisition	-	36,808 Added 39.5%	56,367 Common Stock
Jan 04 2023	SELL Open market or private sale	$42,344 $37.21 p/Share	1,138 Reduced 5.5%	19,559 Common Stock
Mar 01 2022	BUY Grant, award, or other acquisition	-	20,697 Added 50.0%	20,697 Common Stock

Also insider at

KURA

Kura Oncology, Inc. Healthcare

Chief Legal Officer

James Basta

EVP, General Counsel

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NTLA shares.

Notify only if

Value

Insider Trading

Get notified when an Intellia Therapeutics, Inc. insider buys or sells NTLA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Intellia Therapeutics, Inc.

Track Activities on NTLA

Account